相关实验视频
Updated: Sep 16, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
358
塞马格卢提德的不断扩大的作用:超越血糖控制
Malek Zarei1, Masoumeh Sabetkasaei1, Masoud Mozafari2
1Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Evin, Daneshjou Blvd, Koudakyar Ave, Tehran, Iran.
Journal of diabetes and metabolic disorders
|July 7, 2025
概括
作为GLP-1RA的一种,塞马格卢提德通过改善血糖控制和促进显著的体重减轻,有效地管理2型糖尿病和肥胖症. 临床试验证实了它的心血管益处,并扩大了超出代谢障碍的治疗应用.
科学领域:
- 内分泌学和新陈代谢学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 作为一种类似葡萄糖类-1受体激动剂 (GLP-1RA) 的赛马格卢提德 (Semaglutide) 已经彻底改变了2型糖尿病和肥胖症的治疗方法.
- 它的有效性超出了血糖控制范围,包括减肥和心血管保护.
研究的目的:
- 审查塞马格卢提德的作用机制,治疗效益,并扩大临床应用.
- 总结关键临床试验 (SUSTAIN,PIONEER,STEP,FOCUS) 关于其有效性和安全性的证据.
主要方法:
- 临床试验数据的系统综述和新兴的研究关于semaglutide.
- 对葡萄糖平衡,体重管理,心血管结果和其他条件的疗效分析.
主要成果:
- 在试验中显示HbA1c,体重和主要心血管不良事件 (MACE) 的显著降低.
- 在肥胖试验中观察到高达20%的体重减轻,并改善了相关疾病.
- 保护性,抗炎性和潜在的肝保护性作用的证据;扩大在NAFLD,心力衰竭,PCOS,OSA,AUD和阿尔茨海默病中的使用.
结论:
- 塞马格卢提德是代谢,心血管和神经内分泌疾病的基石疗法,得到了强大的临床数据的支持.
- 口服和皮下配方增强了粘附性和可访问性.
- 对于研究不足的人群和非糖尿病心血管疾病和肝纤维化等疾病需要进一步的研究.
相关概念视频
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K

